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Heinrich and Loop (1) recently commented our study on 
the ultra-short term combination treatment of anemia and 
iron deficiency in patients undergoing cardiac surgery (2). 
They discussed whether such treatment might be an option 
in lung cancer surgery and came to the conclusion that 
the optimal approach in lung cancer surgery would be to 
treat preoperative anemia (without specifying by which 
means) and to administer intravenous iron in patients 
with a higher risk of severe postoperative anemia such as 
following neo-adjuvant chemotherapy or pneumonectomy. 
In their imagination, this makes sense, since they initially 
state “iron deficiency seems to be the commonest cause of anemia 
in the surgical population”. Two things are important to 
note in regard to their argument: First, their reference of 
Klein et al., is not at all about iron deficiency but on the 
impact of anemia prior to cardiac surgery (3). Secondly, 
the assumption that because iron deficiency is the most 
common cause of anemia in the surgical population and 
cancer patients are often anemic, iron deficiency must also 
be the most common cause in cancer patients, is a syllogistic 
fallacy.
On a world-wide basis, iron deficiency anemia is 
indeed the most prevalent type of anemia (4). In surgical 
populations iron deficiency anemia as well as isolated iron 
deficiency are associated with increased morbidity and 
mortality (5,6). However, not all anemia is solely due to iron 
deficiency. In patients with cancer, the most common type 
of anemia is anemia of inflammation as recently described 
by Weiss et al. (7). The main mechanisms that finally result 
in anemia in this type of anemia are: (I) iron deficiency 
or reduced iron availability resulting in iron-restricted 
erythropoiesis, (II) reduced erythropoietin response to 
anemia, (III) reduced erythroid cell differentiation upon 
erythropoietin stimulation and (IV) a shortened red blood 
cell life span. Since iron availability is reduced and at the 
same time the erythropoietin response and erythropoietin 
efficacy are blunted, Weiss et al. propose a “combination of 
iron therapy and erythropoiesis-stimulating agents” in such 
patients (7). Combining intravenous iron and subcutaneous 
erythropoietin thus may not only be an option but maybe 
the key to success in patients with anemia of inflammation. 
Treating preoperative anemia in patients undergoing 
lung cancer surgery is important since anemia has 
repeatedly been shown to be a major risk factor for 
mortality (8) and red cell transfusions (8) which additionally 
increase mortality (9). Obviously, the only way out is the 
treatment of preoperative anemia and erythropoietin will 
often be part of such treatment (7). Unfortunately, there 
are concerns regarding the administration of erythropoietin 
with a number of physicians. However, preoperatively we 
are administering a single dose of erythropoietin and in 
numerous meta-analyses preoperative use of erythropoietin 
has been shown to be highly efficacious and not associated 
with side effects (10-12): in the perioperative setting, 
erythropoiesis-stimulating agents successfully reduce blood 
transfusions without increasing the risk of 45-day mortality, 
acute myocardial infarction, bowel ischemia, acute kidney 
injury or thromboembolic events (11). In the critical care 
setting, a meta-analysis of close to 1 million patients found 
the off-label use of erythropoiesis-stimulating agents to 
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be associated with a reduction mortality by a risk ratio of 
0.76 (95% CI: 0.61 to 0.92). The same meta-analysis found 
no evidence of increased myocardial infarction, stroke, 
venous thromboembolism or any adverse events (12). While 
randomized trials are commonly not powered to adequately 
investigate safety profiles, these meta-analyses provide 
evidence on the safety and benefits of erythropoiesis-
stimulating agents in the perioperative setting and in the 
critically ill patient.
Heinrich and Loop further question the transferability of 
a combination anemia treatment into lung cancer surgery. 
They doubt the necessity of such a treatment in light of 
an often 28-day long surgery preparation interval (1). 
While our study was a pragmatic approach to often time 
sensitive cardiac procedures, a longer preparation interval 
may actually improve patient outcomes by allowing more 
time for preoperative hemopoietic recovery. In this setting, 
anemia treatment may be tailored to the cause of anemia. 
Here however, erythropoiesis-stimulating agents are often 
also necessary, if e.g. anemia of inflammation is present (7).
In our original study, we analyzed the acquisition costs of 
red blood cells and combination drug treatment: Total costs 
were higher in the treatment (mean of 1,052±674 Swiss 
Francs) than in the placebo group (mean of 480±704 Swiss 
Francs) (2). In light of the total acquisition costs, Heinrich 
and Loop relinquish an U.S. Food and Drug Administration 
container label extension for red blood cell units that 
states the following contraindication: “Red-cell-containing 
components should not be used to treat anemias that can be 
corrected with specific hematinic medications such as iron, vitamin 
B12, folic acid, or erythropoietin.” (13). While resources may 
be sparse in current healthcare systems, we would advise 
to not neglect evidence-based recommendations for a 
mean saving of 572 Swiss Francs. Further, our study only 
estimated pure acquisition cost of a combination treatment 
or red blood cells. The systemic financial burden of blood 
transfusions is difficult to calculate, but has been estimated 
that transfused patients have a propensity matched mean 
higher total costs of $1,777±36 per admission (14).
In a pragmatic way, patients undergoing major surgery 
resulting a red blood cell transfusion rate of ≥10% or with 
an expected blood loss of ≥500 mL need to be tested for 
hemoglobin concentration, ferritin, transferrin saturation, 
creatinine and C-reactive protein. With these simple 
laboratory data anemia and iron deficiency can be detected, 
the anemia broadly categorized and treated according to an 
algorithm. How this algorithm looks like in detail may be 
left to individual hospitals and incorporate the local drug 
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